-
公开(公告)号：US10450347B2
公开(公告)日：2019-10-22
申请号：US15465218
申请日：2017-03-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Martin Patrick Allen , Ling Li , Claudio Mapelli , Maude A. Poirier , Li-Qiang Sun , Qian Zhao , Eric Mull , Eric P. Gillis , Paul Michael Scola
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US10144706B2
公开(公告)日：2018-12-04
申请号：US15689115
申请日：2017-08-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Kap-Sun Yeung , Katharine A. Grant-Young , Juliang Zhu , Mark G. Saulnier , David B. Frennesson , David R. Langley , Piyasena Hewawasam , Tao Wang , Zhongxing Zhang , Zhaoxing Meng , Li-Qiang Sun , Eric Mull , Paul Michael Scola
IPC: C07D207/12 , C07D217/18 , C07D237/06 , C07D205/04 , C07D207/14 , C07D207/16 , C07D211/22 , C07D211/66 , C07D211/90 , C07D213/38 , C07D213/73 , C07D213/79 , C07D213/85 , C07D231/12 , C07D239/26 , C07D277/28 , C07D295/088 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/14 , C07D401/04 , C07D405/06 , C07D417/12 , C07D211/46 , C07D211/58 , C07D211/60 , C07D213/42 , C07D213/55 , C07C237/04 , C07C235/08 , C07C229/14 , C07C217/58 , C07C217/28 , C07C217/18 , C07C237/06 , C07C255/24 , C07C255/25
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
3.发明申请公开(公告)号：US20170369530A1
公开(公告)日：2017-12-28
申请号：US15672526
申请日：2017-08-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US09732119B2
公开(公告)日：2017-08-15
申请号：US14874886
申请日：2015-10-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Li-Qiang Sun , Qian Zhao , Eric Mull , Eric P. Gillis , Paul Michael Scola
IPC: C07K7/50 , C07K7/54 , A61K38/12 , A01N43/00 , C07K7/64 , A61K45/06 , C07K7/56 , C07K7/08 , A61K38/10 , G01N33/574 , A61K38/00
CPC classification number: C07K7/64 , A61K38/00 , A61K38/10 , A61K38/12 , A61K45/06 , C07K7/08 , C07K7/56 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20170107202A1
公开(公告)日：2017-04-20
申请号：US15290167
申请日：2016-10-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： KAP-SUN YEUNG , Timothy P. Connolly , David B. Frennesson , Katharine A. Grant-Young , Piyasena Hewawasam , David R. Langley , Zhaoxing Meng , Eric Mull , Kyle E. Parcella , Mark George Saulnier , Li-Qiang Sun , Alan Xiangdong Wang , Ningning Xu , Juliang Zhu , Paul Michael Scola
IPC: C07D401/14 , A61K31/5377 , C07D213/85 , A61K31/4439 , C07D401/12 , A61K31/4545 , A61K31/44 , C07D471/04 , C07D405/14 , A61K31/454 , C07D403/12 , A61K31/4025 , A61K31/496 , C07D205/04 , A61K31/397 , A61K31/4427 , A61K31/4453 , C07D211/22 , A61K31/40 , C07D207/14 , C07D207/12 , A61K31/138 , C07C215/20 , C07D413/14 , C07D213/82 , C07D491/08 , C07D417/14 , A61K31/541 , C07D471/08 , C07D405/12 , A61K31/135 , C07D213/80 , C07D207/16 , C07D265/30 , A61K31/5375 , A61K31/166 , C07C235/46 , C07D417/12 , A61K45/06
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
Patent Agency Ranking
公开(公告)号：US09499550B2
公开(公告)日：2016-11-22
申请号：US14434210
申请日：2012-10-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Li-Qiang Sun , Eric Mull , Eric P. Gillis , Michael S. Bowsher , Qian Zhao , Kishore V. Renduchintala , Kandhasamy Sarkunam , Pulicharla Nagalakshmi , P.V.K. Suresh Babu , Paul Michael Scola
IPC: C07D487/04 , C07D519/00 , A61K31/4725 , A61K38/12 , C07B59/00
CPC classification number: C07D487/04 , C07B59/002 , C07B2200/05 , C07D519/00 , C07K5/0804 , C07K5/0827
Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
-
公开(公告)号：US20160175386A1
公开(公告)日：2016-06-23
申请号：US14967960
申请日：2015-12-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Claudio Mapelli , Eric P. Gillis , Li-Qiang Sun , Qian Zhao , Martin Patrick Allen , Eric Mull , Paul Michael Scola
CPC classification number: A61K38/12 , A61K45/06 , C07K7/52 , C07K7/54 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
8.发明申请MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS 审中-公开PD-1 / PD-L1和CD80（B7-1）/ PD-L1蛋白/蛋白质相互作用的MACROCYCLIC抑制剂公开(公告)号：US20160158349A1
公开(公告)日：2016-06-09
申请号：US15009575
申请日：2016-01-28
Applicant: Bristol-Myers Squibb Company
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开提供了抑制PD-1 / PD-L1和PD-L1 / CD80蛋白/蛋白相互作用的新型大环肽，因此可用于改善各种疾病，包括癌症和感染性疾病。
-
公开(公告)号：US08697706B2
公开(公告)日：2014-04-15
申请号：US13628529
申请日：2012-09-27
Applicant: Bristol-Myers Squibb Company
Inventor： Li-Qiang Sun , Qian Zhao , Paul Michael Scola
IPC: C07D498/10 , C07D498/18 , A61K31/529 , A61P31/22
CPC classification number: C07D498/08
Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
-
公开(公告)号：US10882844B2
公开(公告)日：2021-01-05
申请号：US16471531
申请日：2017-12-19
Applicant: Bristol-Myers Squibb Company
Inventor： Kap-Sun Yeung , Katharine A. Grant-Young , Li-Qiang Sun , David R. Langley , Denis R. St. Laurent , Paul M. Scola
IPC: C07D401/12 , C07D413/12 , C07D413/14 , C07D401/14 , C07D471/08
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.081 seconds)
